Summary:
- The article provides a detailed analysis of the European Society of Cardiology (ESC) Congress 2026, focusing on the strategic shift toward incorporating digital health, artificial intelligence, and personalized medicine in cardiovascular clinical trials.
- It evaluates the implications of emerging pharmaceutical pipelines and trial methodologies, specifically highlighting how data-driven endpoints are reshaping the regulatory landscape for heart failure and metabolic disease treatments.